Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 461,086
  • Shares Outstanding, K 28,872
  • Annual Sales, $ 332,070 K
  • Annual Income, $ 18,250 K
  • EBIT $ 23 M
  • EBITDA $ 33 M
  • 60-Month Beta 1.19
  • Price/Sales 1.39
  • Price/Cash Flow 16.21
  • Price/Book 1.05

Options Overview Details

View History
  • Implied Volatility 67.79% ( +3.49%)
  • Historical Volatility 46.34%
  • IV Percentile 28%
  • IV Rank 33.81%
  • IV High 134.09% on 07/15/24
  • IV Low 33.92% on 06/13/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 386
  • Open Int (30-Day) 393

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year 0.31
  • Growth Rate Est. (year over year) -241.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.45 +5.31%
on 05/28/25
19.67 -17.29%
on 05/05/25
-3.08 (-15.92%)
since 05/02/25
3-Month
15.45 +5.31%
on 05/28/25
22.82 -28.69%
on 04/23/25
-5.41 (-24.95%)
since 02/28/25
52-Week
15.45 +5.31%
on 05/28/25
35.84 -54.60%
on 11/05/24
-6.99 (-30.05%)
since 05/31/24

Most Recent Stories

More News
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

CSTL : 16.27 (+1.88%)
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

CSTL : 16.27 (+1.88%)
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

CSTL : 16.27 (+1.88%)
Castle Biosciences Celebrates Skin Cancer Awareness Month

CSTL : 16.27 (+1.88%)
Castle Biosciences Reports First Quarter 2025 Results

CSTL : 16.27 (+1.88%)
Castle Biosciences to Acquire Previse

CSTL : 16.27 (+1.88%)
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

CSTL : 16.27 (+1.88%)
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

CSTL : 16.27 (+1.88%)
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

CSTL : 16.27 (+1.88%)
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

CSTL : 16.27 (+1.88%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 17.46
2nd Resistance Point 16.94
1st Resistance Point 16.60
Last Price 16.27
1st Support Level 15.75
2nd Support Level 15.23
3rd Support Level 14.89

See More

52-Week High 35.84
Fibonacci 61.8% 28.05
Fibonacci 50% 25.65
Fibonacci 38.2% 23.24
Last Price 16.27
52-Week Low 15.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »